Discounted Cash Flow
Cytokinetics Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $106.4m | $16.5m | $35.4m | 15.5% | $0.41 |
| 2017 | $13.4m (-87.4%) | $-127.8m (-876.7%) | $-104.6m (-395.7%) | -955.9% (-6282.4%) | $-2.59 (-731.7%) |
| 2018 | $31.5m (135.6%) | $-106.3m (16.8%) | $-102.1m (2.4%) | -337.4% (64.7%) | — |
| 2019 | $26.9m (-14.7%) | $-121.7m (-14.5%) | $-93.5m (8.4%) | -452.9% (-34.2%) | — |
| 2020 | $55.8m (107.8%) | $-127.3m (-4.6%) | $-2.1m (97.7%) | -228.0% (49.7%) | — |
| 2021 | $70.4m (26.2%) | $-215.3m (-69.2%) | $-191.4m (-8975.1%) | -305.7% (-34.1%) | — |
| 2022 | $94.6m (34.3%) | $-389.0m (-80.6%) | $-310.9m (-62.4%) | -411.2% (-34.5%) | $-4.33 |
| 2023 | $7.5m (-92.0%) | $-526.2m (-35.3%) | $-415.7m (-33.7%) | -6988.6% (-1599.5%) | $-5.45 (-25.9%) |
| 2024 | $18.5m (145.3%) | $-589.5m (-12.0%) | $-399.8m (3.8%) | -3191.1% (54.3%) | $-5.26 (3.5%) |
| 2025 | $88.0m (376.6%) | $-785.0m (-33.2%) | $-534.8m (-33.8%) | -891.6% (72.1%) | $-6.54 (-24.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.